2024 Q1 Form 10-K Financial Statement

#000095017024021651 Filed on February 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $13.05M $51.13M
YoY Change -28.31% -61.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.648M $33.65M
YoY Change 8.93% 3.79%
% of Gross Profit
Research & Development $32.97M $35.27M $133.6M
YoY Change 3.58% 17.98% 12.2%
% of Gross Profit
Depreciation & Amortization $501.0K $506.0K $1.951M
YoY Change 13.61% 11.21% -1.37%
% of Gross Profit
Operating Expenses $41.59M $43.91M $167.4M
YoY Change 3.05% 16.08% 10.37%
Operating Profit $10.82M -$116.2M
YoY Change -131.19% 487.11%
Interest Expense $3.073M $13.16M
YoY Change 2.81% 121.65%
% of Operating Profit
Other Income/Expense, Net $2.975M -$46.00K $13.05M
YoY Change -11.35% -453.85% 121.25%
Pretax Income $13.79M -$27.84M -$103.2M
YoY Change -144.03% 67.41% 642.29%
Income Tax $629.0K $190.0K -$9.383M
% Of Pretax Income 4.56%
Net Earnings $13.16M -$28.03M -$93.80M
YoY Change -137.67% -11.46% 222.91%
Net Earnings / Revenue -214.84% -183.44%
Basic Earnings Per Share $0.31 -$2.23
Diluted Earnings Per Share $0.30 -$0.67 -$2.23
COMMON SHARES
Basic Shares Outstanding 42.18M 42.13M 42.09M
Diluted Shares Outstanding 44.02M 42.09M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $223.6M $223.6M
YoY Change -34.98% -34.98%
Cash & Equivalents $103.2M $111.3M $111.3M
Short-Term Investments $112.4M $112.4M
Other Short-Term Assets $4.749M $4.749M
YoY Change -16.9% -16.9%
Inventory
Prepaid Expenses $3.463M $4.749M
Receivables
Other Receivables $3.377M $4.499M
Total Short-Term Assets $254.7M $243.7M $243.7M
YoY Change -21.77% -31.16% -31.16%
LONG-TERM ASSETS
Property, Plant & Equipment $3.714M $4.215M $7.541M
YoY Change -31.17% -0.31% -21.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $307.0K $396.0K $396.0K
YoY Change -24.75% -20.32% -20.32%
Total Long-Term Assets $8.414M $10.21M $10.21M
YoY Change -21.95% 1.16% 1.16%
TOTAL ASSETS
Total Short-Term Assets $254.7M $243.7M $243.7M
Total Long-Term Assets $8.414M $10.21M $10.21M
Total Assets $263.1M $253.9M $253.9M
YoY Change -21.77% -30.26% -30.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.825M $2.400M $2.400M
YoY Change 88.54% 420.61% 420.61%
Accrued Expenses $26.26M $26.26M
YoY Change 11.54% 11.54%
Deferred Revenue $1.073M $10.22M
YoY Change -97.97% -80.75%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.57M $39.08M $39.08M
YoY Change -62.23% -50.29% -50.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.740M $2.740M
YoY Change -53.86% -53.86%
Total Long-Term Liabilities $2.740M $2.740M
YoY Change -53.86% -53.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.57M $39.08M $39.08M
Total Long-Term Liabilities $2.740M $2.740M
Total Liabilities $31.13M $41.82M $41.82M
YoY Change -63.4% -50.54% -50.54%
SHAREHOLDERS EQUITY
Retained Earnings -$319.9M -$333.1M
YoY Change 16.66% 39.2%
Common Stock $552.0M $545.2M
YoY Change 5.0% 4.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $232.0M $212.1M $212.1M
YoY Change
Total Liabilities & Shareholders Equity $263.1M $253.9M $253.9M
YoY Change -21.77% -30.26% -30.26%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income $13.16M -$28.03M -$93.80M
YoY Change -137.67% -11.46% 222.91%
Depreciation, Depletion And Amortization $501.0K $506.0K $1.951M
YoY Change 13.61% 11.21% -1.37%
Cash From Operating Activities $11.93M -$28.16M -$127.2M
YoY Change -137.54% -5.0% -39590.06%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $398.0K $1.938M
YoY Change -100.0% -123.14% 221.93%
Acquisitions
YoY Change
Other Investing Activities $32.28M $79.98M
YoY Change -0.19% -145.66%
Cash From Investing Activities -$20.32M $31.88M $78.04M
YoY Change 203.86% -6.4% -144.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 375.0K 105.0K 842.0K
YoY Change -9.2% -36.36% -4.32%
NET CHANGE
Cash From Operating Activities 11.93M -28.16M -127.2M
Cash From Investing Activities -20.32M 31.88M 78.04M
Cash From Financing Activities 375.0K 105.0K 842.0K
Net Change In Cash -8.051M 3.828M -48.25M
YoY Change -78.85% -16.53% -72.41%
FREE CASH FLOW
Cash From Operating Activities $11.93M -$28.16M -$127.2M
Capital Expenditures $0.00 $398.0K $1.938M
Free Cash Flow $11.93M -$28.55M -$129.1M
YoY Change -136.99% 2.28% 46005.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001808158
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A8
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2023 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023 rptx Income Tax Examination Year Subject To Examination
IncomeTaxExaminationYearSubjectToExamination
2017 2018 2019 2020 2021 2022 2023
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39335
CY2023 dei Entity Registrant Name
EntityRegistrantName
Repare Therapeutics Inc.
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
7171 Frederick-Banting
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 270
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
St-Laurent
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
CY2023 dei Entity Address Country
EntityAddressCountry
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H4S 1Z9
CY2023 dei City Area Code
CityAreaCode
857
CY2023 dei Local Phone Number
LocalPhoneNumber
412-7018
CY2023 dei Security12b Title
Security12bTitle
Common Shares, no par value
CY2023 dei Trading Symbol
TradingSymbol
RPTX
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
383103514
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42182177
CY2023 dei Auditor Firm
AuditorFirmId
1263
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
Montréal, Canada
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111268000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159521000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
112359000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
184420000
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
10813000
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4499000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4323000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4749000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5715000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
243688000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
353979000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4215000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4228000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3326000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5371000
CY2023Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
2276000
CY2022Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
0
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
396000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
497000
CY2023Q4 us-gaap Assets
Assets
253901000
CY2022Q4 us-gaap Assets
Assets
364075000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2400000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
461000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24057000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
21645000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2400000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2171000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10222000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
53102000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1240000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
39079000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78619000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1010000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3257000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1730000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2682000
CY2023Q4 us-gaap Liabilities
Liabilities
41819000
CY2022Q4 us-gaap Liabilities
Liabilities
84558000
CY2023Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2022Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42176041
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42176041
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42036193
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42036193
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
483350000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
482032000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
61813000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
37226000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-428000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-333109000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239313000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
212082000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279517000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
253901000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
364075000
CY2023 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
51133000
CY2022 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
131830000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
133593000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
119066000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33764000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32560000
CY2023 us-gaap Operating Expenses
OperatingExpenses
167357000
CY2022 us-gaap Operating Expenses
OperatingExpenses
151626000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-116224000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-19796000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-170000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
308000
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
13334000
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
5631000
CY2023 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
119000
CY2022 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
43000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13045000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5896000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103179000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13900000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9383000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15147000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-93796000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29047000
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
456000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-428000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
456000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-428000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-93340000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29475000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.23
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.23
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42093293
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42093293
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41922042
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41922042
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
447000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19691000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-428000
CY2022 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-29047000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279517000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25063000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
456000
CY2023 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-93796000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
212082000
CY2023 us-gaap Profit Loss
ProfitLoss
-93796000
CY2022 us-gaap Profit Loss
ProfitLoss
-29047000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
25063000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
19691000
CY2023 us-gaap Depreciation
Depreciation
1951000
CY2022 us-gaap Depreciation
Depreciation
1978000
CY2023 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
2194000
CY2022 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
2206000
CY2023 rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
-78000
CY2022 rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
298000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7465000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2233000
CY2023 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0
CY2022 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-3620000
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-969000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-593000
CY2023 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
216000
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1385000
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-101000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-89000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1934000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1348000
CY2023 rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
2412000
CY2022 rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3020000
CY2023 rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
151000
CY2022 rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
615000
CY2023 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-14329000
CY2022 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
717000
CY2023 rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-2373000
CY2022 rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-2146000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-43832000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4250000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-127158000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
322000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1938000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
602000
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
259000000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
81400000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
179021000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
256576000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
78041000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-175778000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
153000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
447000
CY2023 rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
689000
CY2022 rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
433000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
842000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
880000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-330000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-48253000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-174906000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
159521000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
334427000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111268000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
159521000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
3089000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1966000
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
4945000
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
10810000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
149000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
86000
CY2023 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-09-06
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-333100000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Our investment portfolio comprises money market funds, U.S. treasury securities, government-sponsored enterprises securities, and commercial paper. Our investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains deposits in accredited financial institutions which exceed insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s exposure to foreign exchange risk is primarily related to fluctuations between the Canadian dollar and the U.S. dollar. There are balances in Canadian dollars which are subject to foreign currency fluctuations relating to the impact of translating to U.S. dollars for financial statement presentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></span>
CY2023 us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of December 31, 2023 and 2022, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
CY2022 us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of December 31, 2023 and 2022, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
CY2023 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2023Q4 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2023Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
400000
CY2022Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
400000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
58600000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
157900000
CY2023 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
500000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-400000
CY2022Q4 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2023Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
1319000
CY2022Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
1280000
CY2023Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
2050000
CY2022Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
1525000
CY2023Q4 rptx Sales Tax And Other Receivables Current
SalesTaxAndOtherReceivablesCurrent
1130000
CY2022Q4 rptx Sales Tax And Other Receivables Current
SalesTaxAndOtherReceivablesCurrent
1518000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4499000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4323000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11519000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9581000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7304000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5353000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4215000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4228000
CY2023 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2023 us-gaap Depreciation
Depreciation
1951000
CY2022 us-gaap Depreciation
Depreciation
1978000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6981000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5616000
CY2023Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
16251000
CY2022Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
15078000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
631000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
680000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
194000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
271000
CY2023Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
24057000
CY2022Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21645000
CY2023 rptx Number Of Operating Leases
NumberOfOperatingLeases
4
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
2372000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
2456000
CY2023 us-gaap Short Term Lease Cost
ShortTermLeaseCost
122000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
33000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
249000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
278000
CY2023 us-gaap Lease Cost
LeaseCost
2743000
CY2022 us-gaap Lease Cost
LeaseCost
2767000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
2405000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1948000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
149000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
86000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y5M15D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y5M4D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.042
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.04
CY2023 rptx Implicit Interest Rate
ImplicitInterestRate
0
CY2022 rptx Implicit Interest Rate
ImplicitInterestRate
0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2490000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1022000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3512000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
102000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3410000
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
10800000
CY2023Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
2300000
CY2023 rptx Income Tax Losses
IncomeTaxLosses
263800000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each common share entitles the holder to one vote on all matters submitted to the shareholders for a vote.
CY2023 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8032902
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.38
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37250000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2371540
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.55
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
64240
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.37
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
242431
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.2
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10097771
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.77
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M28D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13502000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5960917
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M13D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
13000000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4136854
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.88
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M25D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
502000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
500000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1700000
CY2023 rptx Fair Value Of Vested Options
FairValueOfVestedOptions
24400000
CY2022 rptx Fair Value Of Vested Options
FairValueOfVestedOptions
20100000
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
64240
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.37
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000
CY2023 rptx Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares
AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares
100000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25063000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19691000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25063000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19691000
CY2023 rptx Defined Contribution Plan Employer Non Matching Contribution Percent
DefinedContributionPlanEmployerNonMatchingContributionPercent
0.03
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
900000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
800000
CY2023 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
51133000
CY2022 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
131830000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-108362000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-17550000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
5183000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
3650000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103179000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13900000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-9383000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
11527000
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
3620000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9383000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15147000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103179000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13900000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-27342000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3684000
CY2023 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
6648000
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
4899000
CY2023 rptx Income Tax Rate Reconciliation Nondeductible Expense Accounting Charges
IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges
5132000
CY2022 rptx Income Tax Rate Reconciliation Nondeductible Expense Accounting Charges
IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges
679000
CY2023 rptx Income Tax Reconciliation Capital Gain Income Equity Compensation
IncomeTaxReconciliationCapitalGainIncomeEquityCompensation
0
CY2022 rptx Income Tax Reconciliation Capital Gain Income Equity Compensation
IncomeTaxReconciliationCapitalGainIncomeEquityCompensation
-13956000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
4292000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3492000
CY2023 rptx Income Tax Reconciliation State Taxes
IncomeTaxReconciliationStateTaxes
643000
CY2022 rptx Income Tax Reconciliation State Taxes
IncomeTaxReconciliationStateTaxes
-777000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
26000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-142000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
14514000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
34434000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9383000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15147000
CY2023Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
13100000
CY2023 rptx Income Tax Losses Expire One
IncomeTaxLossesExpireOne
115959000
CY2023 rptx Income Tax Losses Expire Two
IncomeTaxLossesExpireTwo
34571000
CY2023 rptx Income Tax Losses Expire Three
IncomeTaxLossesExpireThree
93833000
CY2023 rptx Income Tax Losses Expire Four
IncomeTaxLossesExpireFour
0
CY2023 rptx Income Tax Losses Expire Five
IncomeTaxLossesExpireFive
11394000
CY2023 rptx Income Tax Losses Expire Six
IncomeTaxLossesExpireSix
7111000
CY2023 rptx Income Tax Losses Expire Seven
IncomeTaxLossesExpireSeven
883000
CY2023 rptx Income Tax Losses
IncomeTaxLosses
263751000
CY2023 rptx Scientific Research And Experimental Development Expenditures
ScientificResearchAndExperimentalDevelopmentExpenditures
70700000
CY2023Q4 rptx Investment Tax Credits
InvestmentTaxCredits
11700000
CY2023Q4 rptx Investment Tax Credits Expire One
InvestmentTaxCreditsExpireOne
2649000
CY2023Q4 rptx Investment Tax Credits Expire Two
InvestmentTaxCreditsExpireTwo
2433000
CY2023Q4 rptx Investment Tax Credits Expire Three
InvestmentTaxCreditsExpireThree
2253000
CY2023Q4 rptx Investment Tax Credits Expire Four
InvestmentTaxCreditsExpireFour
1702000
CY2023Q4 rptx Investment Tax Credits Expire Five
InvestmentTaxCreditsExpireFive
1362000
CY2023Q4 rptx Investment Tax Credits Expire Six
InvestmentTaxCreditsExpireSix
776000
CY2023Q4 rptx Investment Tax Credits Expire Seven
InvestmentTaxCreditsExpireSeven
455000
CY2023Q4 rptx Investment Tax Credits Expire Eight
InvestmentTaxCreditsExpireEight
24000
CY2023Q4 rptx Investment Tax Credits
InvestmentTaxCredits
11654000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
69894000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42003000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
18724000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
14468000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1200000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2369000
CY2023Q4 rptx Deferred Tax Assets Net Federal Investment Tax Credits
DeferredTaxAssetsNetFederalInvestmentTaxCredits
8567000
CY2022Q4 rptx Deferred Tax Assets Net Federal Investment Tax Credits
DeferredTaxAssetsNetFederalInvestmentTaxCredits
6589000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4565000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
0
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
39000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
376000
CY2023Q4 rptx Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
-883000
CY2022Q4 rptx Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
-1429000
CY2023Q4 rptx Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
906000
CY2022Q4 rptx Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
1445000
CY2023Q4 rptx Deferred Tax Assets Accrued Expense And Other Liabilities
DeferredTaxAssetsAccruedExpenseAndOtherLiabilities
1134000
CY2022Q4 rptx Deferred Tax Assets Accrued Expense And Other Liabilities
DeferredTaxAssetsAccruedExpenseAndOtherLiabilities
785000
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
3167000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
14783000
CY2023Q4 rptx Deferred Tax Assets Share Based Compensation Cost
DeferredTaxAssetsShareBasedCompensationCost
4240000
CY2022Q4 rptx Deferred Tax Assets Share Based Compensation Cost
DeferredTaxAssetsShareBasedCompensationCost
2492000
CY2023Q4 rptx Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
0
CY2022Q4 rptx Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
13911000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
111553000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
97040000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
111553000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
97040000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
111600000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
97000000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-93796000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29047000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42093293
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42093293
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41922042
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41922042
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.23
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.23
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2023 rptx Increase Decrease In Research And Development Expenses
IncreaseDecreaseInResearchAndDevelopmentExpenses
1500000
CY2022 rptx Increase Decrease In Research And Development Expenses
IncreaseDecreaseInResearchAndDevelopmentExpenses
1400000
CY2023Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
3107000
CY2023Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
33000
CY2023Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
57000
CY2023Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
33000
CY2023Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
41000
CY2023Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
173000
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
3444000
CY2023Q4 us-gaap Foreign Currency Derivative Instruments Not Designated As Hedging Instruments At Fair Value Net
ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet
-3708000
CY2022Q4 us-gaap Foreign Currency Derivative Instruments Not Designated As Hedging Instruments At Fair Value Net
ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet
-6056000
CY2023 rptx Percentage Of Depreciation Usd Against Canadian Dollar
PercentageOfDepreciationUSDAgainstCanadianDollar
0.10
CY2023 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
300000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4215000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4228000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3326000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5371000

Files In Submission

Name View Source Status
0000950170-24-021651-index-headers.html Edgar Link pending
0000950170-24-021651-index.html Edgar Link pending
0000950170-24-021651.txt Edgar Link pending
0000950170-24-021651-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img193244649_0.jpg Edgar Link pending
img193244649_1.jpg Edgar Link pending
img193244649_10.jpg Edgar Link pending
img193244649_11.jpg Edgar Link pending
img193244649_12.jpg Edgar Link pending
img193244649_13.jpg Edgar Link pending
img193244649_14.jpg Edgar Link pending
img193244649_15.jpg Edgar Link pending
img193244649_16.jpg Edgar Link pending
img193244649_17.jpg Edgar Link pending
img193244649_18.jpg Edgar Link pending
img193244649_19.jpg Edgar Link pending
img193244649_2.jpg Edgar Link pending
img193244649_20.jpg Edgar Link pending
img193244649_21.jpg Edgar Link pending
img193244649_22.jpg Edgar Link pending
img193244649_23.jpg Edgar Link pending
img193244649_24.jpg Edgar Link pending
img193244649_25.jpg Edgar Link pending
img193244649_26.jpg Edgar Link pending
img193244649_27.jpg Edgar Link pending
img193244649_28.jpg Edgar Link pending
img193244649_3.jpg Edgar Link pending
img193244649_4.jpg Edgar Link pending
img193244649_5.jpg Edgar Link pending
img193244649_6.jpg Edgar Link pending
img193244649_7.jpg Edgar Link pending
img193244649_8.jpg Edgar Link pending
img193244649_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-20231231.htm Edgar Link pending
rptx-20231231.xsd Edgar Link pending
rptx-ex23_1.htm Edgar Link pending
rptx-ex31_1.htm Edgar Link pending
rptx-ex31_2.htm Edgar Link pending
rptx-ex32_1.htm Edgar Link pending
rptx-ex97.htm Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
rptx-20231231_htm.xml Edgar Link completed